Journal Article

FZJ-2018-06329

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2

Schemmert, S.FZJ* ; Schartmann, E. ; Honold, D.FZJ* ; Zafiu, C.FZJ* ; Ziehm, T.FZJ* ; Langen, K.-J.FZJ* ; Shah, N. J.FZJ* ; Kutzsche, J.FZJ* ; Willuweit, A. (Corresponding author)FZJ* ; Willbold, D. (Corresponding author)FZJ*

2019
Academic Press Orlando, Fla.

This record in other databases:      

Please use a persistent id in citations: http://hdl.handle.net/2128/20462  doi:10.1016/j.nbd.2018.10.021

Abstract: Alzheimer's disease, a multifactorial incurable disorder, is mainly characterised by progressive neurodegeneration, extracellular accumulation of amyloid-β protein (Aβ), and intracellular aggregation of hyperphosphorylated tau protein. During the last years, Aβ oligomers have been claimed to be the disease causing agent. Consequently, development of compounds that are able to disrupt already existing Aβ oligomers is highly desirable. We developed d-enantiomeric peptides, consisting solely of d-enantiomeric amino acid residues, for the direct and specific elimination of toxic Aβ oligomers. The drug candidate RD2 did show high oligomer elimination efficacy in vitro and the in vivo efficacy of RD2 was demonstrated in treatment studies by enhanced cognition in transgenic mouse models of amyloidosis. Here, we report on the in vitro and in vivo efficacy of the compound towards pyroglutamate-Aβ, a particular aggressive Aβ species. Using the transgenic TBA2.1 mouse model, which develops pyroglutamate-Aβ(3–42) induced neurodegeneration, we are able to show that oral RD2 treatment resulted in a significant deceleration of the progression of the phenotype. The in vivo efficacy against this highly toxic Aβ species further validates RD2 as a drug candidate for the therapeutic use in humans.

---

Contributing Institute(s):

1. Strukturbiochemie (ICS-6)
2. Physik der Medizinischen Bildgebung (INM-4)

Research Program(s):

1. 553 - Physical Basis of Diseases (POF3-553) (POF3-553)

Appears in the scientific report 2018

---

Database coverage:
; ; ; BIOSIS Previews ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---